JPRN-jRCT2080221754招募中3 期
A Phase 3 Study of LY2189265 Monotherapy Compared to Placebo and Liraglutide in Patients with Type 2 Diabetes Mellitus
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Participants who have had a diagnosis of type 2 diabetes mellitus before screening
- •-Participants who have been OAM-naive (diet and exercise only) or been taking OAM monotherapy except for thiazolidinedione (TZD) and are willing to discontinue this medication. Participants taking OAM monotherapy must complete 8-week washout period prior to randomization
- •-Participants who are OAM naive with screening glycosylated hemoglobin (HbA1c) value of 7.0% to 10.0% and randomization HbA1c value of 7.0% to 10.0%, or who are taking OAM monotherapy with screening HbA1c value of 6.5% to 9.0% and randomization HbA1c value of 7.0% to 10.0%.
- •-Participants who have a body mass index (BMI) of 18.5kg/m2 to 35.0kg/m2
排除标准
- 未提供
研究者
相似试验
已完成
3 期
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT01558271Eli Lilly and Company492
进行中（未招募）
1 期
A study in patients with Myelodysplastic SyndromesMyelodysplastic SyndromesMedDRA version: 14.1Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851EUCTR2013-003235-30-ESilly S.A.140
进行中（未招募）
1 期
A study in patients with Myelodysplastic SyndromesMyelodysplastic SyndromesMedDRA version: 14.1Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851EUCTR2013-003235-30-ITEli Lilly and Company43
进行中（未招募）
1 期
A study in patients with Myelodysplastic SyndromesMyelodysplastic SyndromesMedDRA version: 17.1Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851EUCTR2013-003235-30-DEEli Lilly and Company140
已完成
3 期
A randomized phase III study of monotherapy docetaxel or intercalated erlotinib docetaxel combination therapy in patients with relapsed EGFR wild type, ALK negative non squamous cell carcinoma. (NVALT 18 study)<br>lung carcinoma10038666lung cancerNL-OMON45166Stichting NVALT studies230